"Ozempic Breakthrough: Higher Doses, Cardiovascular Benefits, and Emerging Challenges Revealed"

# Ozempic Updates: Higher Doses, Cardiac Benefits, and User Challenges | Navigating Ozempic Podcast

In this comprehensive episode of Navigating Ozempic, we explore groundbreaking developments in GLP-1 medications. Discover how triple-dose Ozempic (7.2mg weekly) significantly enhances weight loss outcomes without increasing side effects, according to new Lancet research. We dive into Novo Nordisk's REACH study showing Ozempic reduces cardiovascular events by 23% in older adults compared to dulaglutide.

We also address concerning trends - why 50% of users discontinue within a year due to cost barriers, and how emotional eaters may experience different results than those triggered by external food cues. The episode covers mounting legal concerns, with over 2,600 lawsuits alleging severe gastrointestinal complications and potential vision loss.

Whether you're a current user, considering Ozempic, or a healthcare professional, this episode delivers essential updates on maximizing benefits, managing risks, and understanding the evolving landscape of this revolutionary medication. Stay informed on the latest research, real-world outcomes, and patient experiences shaping Ozempic treatment protocols.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Episode Transcript

Speaker 1 (00:00):
Welcome back to Navigating Ozepic, where we keep you informed
on everything shaping the world of ozepic, from medical breakthroughs
to headline making lifestyle debates. As of this week, there
have been significant updates across clinical research, real world treatment outcomes,
legal developments, and what uses need to know about sticking
with this much discussed medication. The biggest medical news this

(00:25):
week comes from a new clinical trial reported in the
Lancet Diabetes and Endochronology and highlighted by drugs dot Com,
which found that a triple sized weekly dose of ozempic
specifically seven point two milligrams per week can significantly improve
weight loss for people living with obesity, all without leading

(00:45):
to marked addition, and the basic side would need to
be more overrated to the highest od subsidiary. This research
compared the higher dose with the current approved maximum of
two point four milligrams and with the placebo. Participants receiving
the seven point two milligram dose over seventy two weeks
saw more considerable weight loss, suggesting that those not reaching

(01:08):
their weight loss goals with the standard dose of a
zepic could benefit from a higher dosage under proper medical supervision.
For older adults, especially those managing type two diabetes and
cardiovascular disease, there is encouraging new real world evidence. Novo
Nordisk announced results from the REACH study presented at the
European Association for the Study of Diabetes meeting in Vienna,

(01:32):
revealing that ozepic reduced the risk of major cardiovascular events
meaning heart attacks, strokes, or cardiovascular related debts by twenty
three per cent compared to doula glutide, another GLP one
receptor agonist. These results were based on nearly sixty thousand
Medicare patients in the United States aged sixty six and older,

(01:54):
a population often at higher risk and less frequently represented
in randomized controlled trial. In addition to the twenty three
percent reduced risk for major events, ozepic users also had
a twenty six percent lower risk of death versus those
on delaglutide. These finding strengthen ozempic's reputation ionian as not

(02:16):
just a blood sugar and weight management drug, but also
a potentially powerful tool for protecting against some of the
most serious complications of diabetes. However, as the popularity of
ozempic continues to surge, new challenges and considerations are emerging.
A study from Denmark reported by drugs dot Com found
that about half of the people prescribed ozepic for weight

(02:37):
loss stop using it within one year. The primary barrier
cited by researches is the high cost of the medication,
which seems to lead people to abandon the therapy before
seeing long term benefits. This drop off rate is concerning
to experts because for ozepic to work effectively, especially for
appetite control and sustained weight loss, it needs to taken

(03:01):
continuously as prescribed. Once the medication is stopped, all those
games can be quickly lost. On the subject of who
benefits most from ozempic, an interesting Japanese study published in
Frontiers and Clinical Diabetes and Healthcare found that not all
eaters respond the same way to GLP one therapies. People

(03:23):
who are prone to emotional eating, meaning they eat more
in response to negative feelings rather than to tempting external
cues like food, smells or sites, were less likely to
lose significant weight on ozempic. In contrast, individuals whose overeating
is mainly triggered by external stimuli had a better response.

(03:44):
This suggests that understanding a person's eating patterns before starting
therapy could help predict how successful they might be with
ozempic and related medications. The landscape of obesity management is
also shifting as these medications become more mainstream. Experts at
Temple University last week cautioned healthcare professionals, including plastic surgeons

(04:05):
prescribing these medications before weight loss surgeries, to seek additional
training and collaborate closely with obesity specialists the surgeon. Popularity
for GLP one drugs like ozepic means more diverse groups
of patients are trying them, some of whom may need
extra support to manage side effects, maximize benefits, and make
informed choices about their care plan. Another critical piece of

(04:29):
news involves ongoing legal action. According to drug watch dot com,
lawsuits are mounting alleging that ozepic can cause severe gastrointestinal
problems like gastra paresis, which is a form of stomach paralysis,
as well as alias and even vision loss. Plaintiffs claim
they were not properly warned of these risks. As of

(04:49):
September twenty twenty five, there are two thousand, six hundred
and seventy six personal injury lawsuits mainly centered on gastroparesis
and related complications consolidated in federal court in the Eastern
District of Pennsylvania. The U S Food and Drug Administration
did add a warning about intestinal blockage to ozempic in
September twenty twenty three, but some legal experts argue the

(05:11):
risk of gastroparesis was not emphasized early enough. There have
also been active legal pursuits connecting ozempic to vision loss,
specifically a condition called non arteritic antier ischemic optic neuropathy,
which can cause permanent vision impairment. While these lawsuits have
not reached settlement or judgment yet, they highlight the absolute

(05:32):
importance of patients and their health care providers monitoring for
severe gastri intestinal or vision symptoms and promptly seeking medical
advice if they occur. Most users, according to medical reviews,
will experience side effects like nausea, vomiting, or a feeling
of forness. For the rare but serious complications, Heightened awareness

(05:54):
and swift medical attention are the best safeguards for listeners
taking ozempic or considering it. All. This news underscores the
importance of regular check ins with your health care team
and carefully weighing the benefits and potential risks. If cost
is a barrier, discussing financial assistance programs or alternative therapies
may keep you on track with your health goals. If

(06:15):
you find yourself struggling to stick with the medication, or
if eating habits are standing in your way, don't hesitate
to ask about support services, counseling, or nutritional guidance to
improve your chance